Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) EPS (Weighted Average and Diluted) (2021 - 2025)

Serina Therapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.45 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 446.15% year-over-year to -$0.45; the TTM value through Sep 2025 reached $1.63, up 135.59%, while the annual FY2024 figure was -$1.51, 306.85% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.45 at Serina Therapeutics, up from -$0.66 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.23 in Q4 2024 and bottomed at -$69.0 in Q2 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.06 (2022), against an average of -$5.08.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 3208.41% in 2022 before it skyrocketed 1918.75% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2021, then plummeted by 373259.9% to -$9.5 in 2022, then skyrocketed by 101.68% to $0.16 in 2023, then surged by 1918.75% to $3.23 in 2024, then plummeted by 113.93% to -$0.45 in 2025.
  • Per Business Quant, the three most recent readings for SER's EPS (Weighted Average and Diluted) are -$0.45 (Q3 2025), -$0.66 (Q2 2025), and -$0.49 (Q1 2025).